CCF Celebrates FDA Approval of TRUSELTIQ™ for Cholangiocarcinoma Patients Developed by BridgeBio Pharma Affiliate QED Therapeutics

On behalf of patients and families impacted by cholangiocarcinoma, the Cholangiocarcinoma Foundation (CCF) celebrates the U.S. Food and Drug Administration (FDA) approval of TRUSELTIQ™ (infigratinib) for patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. TRUSELTIQ™ is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR, developed by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc.

“This is an important milestone for this community and specifically for patients with CCA harboring an FGFR2-fusion,” said Stacie Lindsey, Founder and CEO, CCF. “We want to acknowledge all who participated in this trial and thank them for playing such a critical role. We are hopeful about the potential TRUSELTIQ™ offers people living with this debilitating cancer.

“This recent approval is evidence of the value of collaboration among and between industry and patient advocacy organizations,” said Jason Scott, Chair of the Board of Directors, Cholangiocarcinoma Foundation.

"FGFR2-fusion-driven cholangiocarcinoma is an aggressive malignancy with a poor prognosis," said Susan Moran, M.D., M.S.C.E., Chief Medical Officer of QED Therapeutics, an affiliate of BridgeBio. "We are excited about the promise TRUSELTIQ™ holds as a new treatment option for people with cholangiocarcinoma who have recurred after first-line therapy and are in need of further treatment. We extend our gratitude to the Cholangiocarcinoma Foundation for its continued partnership and support, and also thank every person who participated in our clinical trials, along with the researchers who helped advance this therapy for people in serious need."